Du Jia, Sun Yang, Lu Yi-Yu, Lau Eric, Zhao Ming, Zhou Qian-Mei, Su Shi-Bing
Research Center for Traditional Chinese Medicine Complexity System, Shanghai University of Traditional Chinese Medicine, Shanghai, P.R. China.
Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, CA, U.S.A.
Anticancer Res. 2017 Nov;37(11):6141-6151. doi: 10.21873/anticanres.12063.
BACKGROUND/AIM: The synergistic combinations of natural products have long been the basis of Traditional Chinese herbal Medicine formulas. In this study, we investigated the synergistic effects of a combination of berberine and evodiamine against human breast cancer MCF-7 cells in vitro and in vivo, and explored its mechanism.
Cell survival was measured using the MTT assay. Apoptosis-related proteins were observed using western blot analysis. Apoptosis was detected with flow cytometric analysis and by Hoechst 33258 staining. Tumor xenografts were used in vivo.
Compared to berberine or evodiamine treatments alone, the combination treatment of berberine (25 μM) and evodiamine (15 μM) synergistically inhibited the proliferation of MCF-7 cells in a time-dependent manner and resulted in the G/G phase accumulation of cells that exhibited increased expression levels of the CDK inhibitors p21 and p27 with a concomitant reduction in the expression levels of cell-cycle checkpoint proteins cyclin D1, cyclin E, CDK4, and CDK6. Furthermore, the combination treatment induced apoptosis that was accompanied by increased expression levels of p53 and Bax, reduced expression levels of Bcl-2, activation of caspase-7, and caspase-9, and the cleavage of PARP. The combination of berberine and evodiamine synergistically inhibited tumor growth in vivo in MCF-7 human breast cancer xenografts.
Combination of berberine and evodiamine acts synergistically to suppress the proliferation of MCF-7 cells by inducing cell cycle arrest and apoptosis, illustrating the potential synergistic and combinatorial application of bioactive natural products.
背景/目的:天然产物的协同组合长期以来一直是中药方剂的基础。在本研究中,我们调查了黄连素和吴茱萸碱联合用药对人乳腺癌MCF-7细胞的体内外协同作用,并探讨其作用机制。
采用MTT法检测细胞存活率。通过蛋白质免疫印迹分析观察凋亡相关蛋白。用流式细胞术分析和Hoechst 33258染色检测细胞凋亡。体内实验采用肿瘤异种移植模型。
与单独使用黄连素或吴茱萸碱处理相比,黄连素(25 μM)和吴茱萸碱(15 μM)联合处理以时间依赖性方式协同抑制MCF-7细胞的增殖,并导致细胞在G/G期积累,表现为细胞周期蛋白依赖性激酶(CDK)抑制剂p21和p27表达水平升高,同时细胞周期检查点蛋白细胞周期蛋白D1、细胞周期蛋白E、CDK4和CDK6的表达水平降低。此外,联合处理诱导细胞凋亡,伴随着p53和Bax表达水平升高、Bcl-2表达水平降低、半胱天冬酶-7和半胱天冬酶-9激活以及聚(ADP-核糖)聚合酶(PARP)裂解。黄连素和吴茱萸碱联合用药在体内对MCF-7人乳腺癌异种移植瘤具有协同抑制肿瘤生长的作用。
黄连素和吴茱萸碱联合用药通过诱导细胞周期阻滞和凋亡协同抑制MCF-7细胞的增殖,说明了生物活性天然产物潜在的协同和联合应用价值。